Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Vince B. C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen-de Jong, Bas Oldenburg, Nanne K. de Boer, Mark Loewenberg, Nidhi Srivastava, Alexander G. L. Bodelier, Rachel L. West, Jeroen M. Jansen, Annemarie C. de Vries, Jeoffrey J. L. Haans, Dirk J. de Jong, Marie J. Pierik, Frank Hoentjen*, Dutch Initiative Crohn and Colitis

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)

Abstract

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index

Original languageEnglish
Pages (from-to)1189-1199
Number of pages11
JournalClinical Pharmacology & Therapeutics
Volume107
Issue number5
Early online date11 Dec 2019
DOIs
Publication statusPublished - May 2020

Keywords

  • LONG-TERM EFFECTIVENESS
  • MAINTENANCE THERAPY
  • MULTICENTER COHORT
  • INDUCTION
  • SAFETY
  • IMPACT

Cite this